Login / Signup

Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.

John A LigonWoonyoung ChoiGady CojocaruWei FuEmily Han-Chung HsiueTeniola F OkeNicholas SiegelMegan H FongBrian LadleChristine A PratilasCarol D MorrisAdam LevinDaniel S RheeChristian F MeyerAda J TamRichard BlosserElizabeth D ThompsonAditya SuruDavid McConkeyFranck HousseauRobert AndersDrew M PardollNicolas J Llosa
Published in: Journal for immunotherapy of cancer (2022)
Osteosarcoma PMs exhibit immune exclusion characterized by the accumulation of TILs at the PM interface. These TILs produce effector cytokines, suggesting their capability of activation and recognition of tumor antigens. Our findings suggest cooperative immunosuppressive mechanisms in osteosarcoma PMs including immune checkpoint molecule expression and the presence of immunosuppressive myeloid cells. We identify cellular and molecular signatures that are associated with patient outcomes, which could be exploited for successful immunotherapy.
Keyphrases